LIXA is focused on developing scalable antibiofilm technologies to treat antimicrobial resistance (AMR), for anyone, anything and anywhere. Our technologies disrupt both mature and immature biofilms and are compatible with most existing antimicrobials. We are open to partnerships to develop real sol...See more
Headquarter Australia |
Countries of operation Australia |
Year founded 2021 (3 years) |
Funding status Series A |
Company type SME |
Quality Manager
Research And Development Officer
Discovery Research Officer